[ZHANG, Lijia 张丽佳, ZHANG, Lijia 张丽佳, LI, Zhiming 李志明, ZHANG, Lijia 张丽佳, LI, Zhiming 李志明, CAO, Longyu 曹龙雨] Huawei Administration Building 中国广东省深圳市龙岗区坂田华为总部办公楼, Guangdong 518129Bantian, Longgang DistrictShenzhen, Guangdong 518129 Embodiments of the present invention provide a key issuing method, a method for implementing authorization checking on a UE, and related devices. The key issuing method comprises: generating a multimedia broadcast multicast service key (MSK); establishing or acquiring, from a broadcast multicast service center (BM-SC), a mapping between the MSK and a group identifier and/or a service identifier of each group communication service enabler (GCSE) group; and sending the generated MSK to a user equipment (UE) in the corresponding GCSE group according to the mapping between the MSK and the group identifier and/or the service identifier of each GCSE group. According to the embodiments of the present invention, in the precondition that the BM-SC is invisible to the GCSE group, it is ensured that the service authorization checking on the UE is realized by the BM-SC in a scenario where an MBMS security mechanism is completely reused, and the MSK can be issued by a GCS AS in a scenario where the MBMS security mechanism is partially reused, so that the communication security can be guaranteed by means of the MBMS security mechanism.

[JIANG, Peng 蒋鹏, GUO, Linfeng 郭林峰, ZHOU, Linjun 周林俊, SUN, Ningyuan 孙宁远, XIAO, Lin 肖琳, YU, Jianghong 余江虹, CHEN, Junying 陈俊英, LI, Lijia 李利佳, LI, Yong 李勇, LI, Ming 李明, LI, Xiaoping 李晓平, LI, Jing 李静, LI, Wenjia 李文佳] {Northern Industrial Area, Songshan Lake 中国广东省东莞市松山湖北部工业园, Guangdong 523000Dongguan, Guangdong 523000;CN CN(CN)(CN)} A triple-receptor agonist. The agonist comprises a polypeptide represented by formula (I), X 1X 2X 3GTX 6TSDYSIX 13X 14DX 16X 17X 18X 19X 20X 21FX 23X 24X 25LX 27X 28GGPSSGAPPPS (I), wherein X 1 is Y or H; X 2 is Aib; X 3 is Q or H; X 6 is an unnatural amino acid; X 13 is L or Y; X 14 is L or K; X 16 is E, K, or R; X 17 is K, R, or I; X 18 is A, R, or K; X 19 is Q or A; X 20 is R, K, Q, H, or Aib; X 21 is D, A, or E; X 23 is I or V; X 24 is E or Q; X 25 is W or Y; X 27 is I or L; and X 28 is E or A. The agonist has relatively strong agonistic activity on the three receptors GLP-1, GCG, and GIP and can be used for treating diseases related to metabolic disorders. A triple-receptor agonist. The agonist comprises a polypeptide represented by formula (I), X 1X 2X 3GTX 6TSDYSIX 13X 14DX 16X 17X 18X 19X 20X 21FX 23X 24X 25LX 27X 28GGPSSGAPPPS (I), wherein X 1 is Y or H; X 2 is Aib; X 3 is Q or H; X 6 is an unnatural amino acid; X 13 is L or Y; X 14 is L or K; X 16 is E, K, or R; X 17 is K, R, or I; X 18 is A, R, or K; X 19 is Q or A; X 20 is R, K, Q, H, or Aib; X 21 is D, A, or E; X 23 is I or V; X 24 is E or Q; X 25 is W or Y; X 27 is I or L; and X 28 is E or A. The agonist has relatively strong agonistic activity on the three receptors GLP-1, GCG, and GIP and can be used for treating diseases related to metabolic disorders.

[LI, Lijia 李利佳, GU, Xiangdi 古想娣, WU, Du 吴都, GUO, Linfeng 郭林峰, LI, Xiaoping 李晓平, HU, Yulong 胡育龙, LI, Yusheng 李宇晟, LI, Yu 李玉, XU, Linghua 许玲华, LI, Jing 李静, CHEN, Xiaofeng 陈小锋, LI, Wenjia 李文佳] Room102, Building 7, No.368, Zhenan Road, Changan Town 中国广东省东莞市长安镇长安振安中路368号7号楼102室, Guangdong 523871Dongguan, Guangdong 523871 Disclosed is a polypeptide. The polypeptide has a modification at the N-terminus compared with polypeptides having the following amino acid sequences: (1) a polypeptide having the amino acid sequences represented by SEQ ID NOs: 1 to 6; or (2) a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to (1); or (3) a polypeptide with substitution, deletion and/or addition of one or more amino acids compared with (1), wherein the modification comprises at least one modification selected from addition, methylation, formylation, carbamylation, succinylation, cyclization, lysine propionylation, hexadecanoylation, myristylation, and acetylation of N-terminal amino acids. The polypeptide not only maintains the activity of BefA proteins to promote the proliferation of beta-cells, but also has the characteristics of higher stability and difficult degradation. Furthermore, the polypeptide also has the potential to lower glucose, promote weight loss, and protect the liver. Disclosed is a polypeptide. The polypeptide has a modification at the N-terminus compared with polypeptides having the following amino acid sequences: (1) a polypeptide having the amino acid sequences represented by SEQ ID NOs: 1 to 6; or (2) a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to (1); or (3) a polypeptide with substitution, deletion and/or addition of one or more amino acids compared with (1), wherein the modification comprises at least one modification selected from addition, methylation, formylation, carbamylation, succinylation, cyclization, lysine propionylation, hexadecanoylation, myristylation, and acetylation of N-terminal amino acids. The polypeptide not only maintains the activity of BefA proteins to promote the proliferation of beta-cells, but also has the characteristics of higher stability and difficult degradation. Furthermore, the polypeptide also has the potential to lower glucose, promote weight loss, and protect the liver.

[JIANG PENG, GUO LINFENG, ZHOU LINJUN, SUN NINGYUAN, XIAO LIN, YU JIANGHONG, CHEN JUNYING, LI LIJIA, LI YONG, LI MING, LI XIAOPING, LI JING, LI WENJIA] CN A triple-receptor agonist. The agonist comprises a polypeptide represented by formula (I), X

[LIN, Shushan 林树珊, LI, Xiang 李想, DONG, Junji 董军纪, PENG, Ju 彭菊, JIA, Xingfan 贾兴繁, ZHOU, Linjun 周林俊, ZHANG, Kuo 张阔, REN, Zhiheng 任志衡, LI, Kaifeng 李凯峰, XU, Yucheng 徐宇骋, QU, Daixin 屈代鑫, CHEN, Xixin 陈锡欣, LI, Lijia 李利佳, KANG, Ning 亢宁, CHEN, Limo 陈立模, CHEN, Xiaofeng 陈小锋, LI, Wenjia 李文佳] Northern Industrial Area, Songshan Lake 中国广东省东莞市松山湖北部工业园, Guangdong 523000Dongguan, Guangdong 523000 Disclosed in the present invention are a bispecific antibody and an application thereof. The antibody comprises: a first peptide chain comprising an antibody first heavy chain variable region and a heavy chain constant region, wherein the heavy chain constant region comprises a CH1 region, a first hinge region, and a first Fc region; a second peptide chain comprising an antibody first light chain variable region and a light chain constant region; and a third peptide chain comprising a single chain antibody, a second hinge region, and a second Fc region, wherein the antibody heavy chain variable region and the antibody light chain variable region have a first antigen binding activity; the single chain antibody has a second antigen binding activity; the first peptide chain is connected to the second peptide chain by means of a disulfide bond; the first hinge region is connected to the second hinge region by means of a disulfide bond; and the first Fc region is connected to the second Fc region by means of a Knobs-into-hole structure. The antibody can effectively inhibit tumor growth and reduce the possibility of cytokine storm, and thus has high safety. Disclosed in the present invention are a bispecific antibody and an application thereof. The antibody comprises: a first peptide chain comprising an antibody first heavy chain variable region and a heavy chain constant region, wherein the heavy chain constant region comprises a CH1 region, a first hinge region, and a first Fc region; a second peptide chain comprising an antibody first light chain variable region and a light chain constant region; and a third peptide chain comprising a single chain antibody, a second hinge region, and a second Fc region, wherein the antibody heavy chain variable region and the antibody light chain variable region have a first antigen binding activity; the single chain antibody has a second antigen binding activity; the first peptide chain is connected to the second peptide chain by means of a disulfide bond; the first hinge region is connected to the second hinge region by means of a disulfide bond; and the first Fc region is connected to the second Fc region by means of a Knobs-into-hole structure. The antibody can effectively inhibit tumor growth and reduce the possibility of cytokine storm, and thus has high safety.

[JIANG, Peng, XIAO, Lin, ZHOU, Linjun, HUANG, Limei, YANG, Min, JIANG, Yan, SUN, Ningyuan, MAO, Jianming, LI, Yong, LI, Lijia, GUO, Linfeng, LI, Jing, LI, Wenjia] Northern Industrial Area Songshan Lake, Dongguan, Guangdong 523000, CN A GLP-1/GIP dual-targeted polypeptide, containing a first polypeptide having the following amino acid sequence : X＜sub＞1＜/sub＞X＜sub＞2＜/sub＞X＜sub＞3＜/sub＞GT FX＜sub＞4＜/sub＞SDY SX＜sub＞5＜/sub＞X＜sub＞6＜/sub＞X＜sub＞7＜/sub＞X＜sub＞8＜/sub＞ X＜sub＞9＜/sub＞X＜sub＞10＜/sub＞X＜sub＞11＜/sub＞X＜sub＞12＜/sub＞X＜sub＞13＜/sub＞ X＜sub＞14＜/sub＞FX＜sub＞15＜/sub＞X＜sub＞16＜/sub＞W LX＜sub＞17＜/sub＞X＜sub＞18＜/sub＞X＜sub＞19＜/sub＞, wherein X＜sub＞1＜/sub＞ is Y or H, X＜sub＞2＜/sub＞ is A or G or S, X＜sub＞3＜/sub＞ is E or Q, X＜sub＞4＜/sub＞ is I or T, X5 is I or K, X＜sub＞6＜/sub＞ is A or Y or L or I, X＜sub＞7＜/sub＞ is M or L, X＜sub＞8＜/sub＞ is D or E, X＜sub＞9＜/sub＞ is K or E, X＜sub＞10＜/sub＞ is I or Q or K or E or L, X＜sub＞11＜/sub＞ is H or A or R, X＜sub＞12＜/sub＞ is A or Q or V, X＜sub＞13＜/sub＞ is K or Q or R or H, X＜sub＞14＜/sub＞ is D or E or A or L, X＜sub＞15＜/sub＞ is V or I, X＜sub＞16＜/sub＞ is N or E or D or Q, X＜sub＞17＜/sub＞ is L or I or K or V, X＜sub＞18＜/sub＞ is A or E or K, X＜sub＞19＜/sub＞ is Q or G; X＜sub＞1＜/sub＞~X＜sub＞13＜/sub＞ do not satisfy at the same time that X＜sub＞1＜/sub＞ is Y, X＜sub＞2＜/sub＞ is A, X＜sub＞3＜/sub＞ is E, X＜sub＞4＜/sub＞ is I, X＜sub＞5＜/sub＞ is I, X＜sub＞6＜/sub＞ is A, X＜sub＞7＜/sub＞ is M, X＜sub＞8＜/sub＞ is D, X＜sub＞9＜/sub＞ is K, X＜sub＞10＜/sub＞ is I, X＜sub＞11＜/sub＞ is H, X＜sub＞12＜/sub＞ is Q, X＜sub＞13＜/sub＞ is Q, X＜sub＞14＜/sub＞ is D, X＜sub＞15＜/sub＞ is V, X＜sub＞16＜/sub＞ is N, X＜sub＞17＜/sub＞ is L, X＜sub＞18＜/sub＞ is A, X＜sub＞19＜/sub＞ is Q. The GLP-1/GIP dual-targeted polypeptide can effectively reduce the weight and blood sugar level.

[WENTING LI, HONGQIANG LI, LIJIA ZHANG, YANHAN LI] CN Disclosed are an industrial water-saving agent and a preparation method thereof. The preparation method comprises the following steps: (1) with the total amount of white oil of 100 parts by weight, adding 60%-90% of the total amount of white oil to a product kettle for pre-heating; (2) adding the white oil remaining in the step (1) to a mixing kettle for heating, and adding 6.0-18.6 parts by weight of functional additives (added externally, hereinafter the same) to the mixing kettle, mixing uniformly, and preparing into mother liquid; and(3) adding the mother liquid into the mixing kettle in the step (2) to the product kettle in the step (1), and stirring uniformly. The industrial water-saving agent has a good barrier effect on water vapor, small dose, and significant water-saving effect; in addition, the industrial water-saving agent is easy to use without any addition or replacement of system equipment.

[REN, Zhiheng 任志衡, DONG, Junji 董军纪, WEI, Xiling 危喜玲, LI, Xiang 李想, LIN, Shushan 林树珊, JIA, Xingfan 贾兴繁, ZHANG, Kuo 张阔, LI, Lijia 李利佳, XU, Yuli 许玉丽, CHEN, Limo 陈立模, LI, Wenjia 李文佳] Northern Industrial Area, Songshan Lake 中国广东省东莞市松山湖北部工业园, Guangdong 523808Dongguan, Guangdong 523808 The present invention relates to a TrkA antigen epitope peptide and a use thereof. The epitope peptide comprises an amino acid sequence as shown in SEQ ID NO: 4. The present invention obtains a dominant antigenic epitope of a TrkA antigen by means of hydrogen-deuterium exchange mass spectrometry. An anti-TrkA antibody that specifically binds thereto can block the binding of a TrkA receptor to the ligand NGF, and inhibit or weaken NGF/TrKA signaling involving TrkA, thereby effectively relieving pain and hyperalgesia. The present invention relates to a TrkA antigen epitope peptide and a use thereof. The epitope peptide comprises an amino acid sequence as shown in SEQ ID NO: 4. The present invention obtains a dominant antigenic epitope of a TrkA antigen by means of hydrogen-deuterium exchange mass spectrometry. An anti-TrkA antibody that specifically binds thereto can block the binding of a TrkA receptor to the ligand NGF, and inhibit or weaken NGF/TrKA signaling involving TrkA, thereby effectively relieving pain and hyperalgesia.

[LI, Xiang 李想, ZHANG, Hui 张慧, REN, Zhiheng 任志衡, ZHOU, Linjun 周林俊, PENG, Ju 彭菊, LIN, Shushan 林树珊, LI, Zhaofeng 李钊锋, XIAO, Lin 肖琳, WAN, Dan 万丹, DONG, Junji 董军纪, XU, Yatao 许亚韬, LI, Lijia 李利佳] Northern Industrial Area, Songshan Lake 中国广东省东莞市松山湖北部工业园, Guangdong 523000Dongguan, Guangdong 523000 Provided are an anti-FGFR2b antibody and the use thereof. Provided are a novel anti-FGFR2b antibody and a nucleic acid encoding the antibody, a vector and a host cell for the expression and production thereof, an antibody-drug conjugate, and a pharmaceutical composition comprising the antibody. Furthermore, the present invention relates to the use of the antibody in the ‌diagnosis‌ of an FGFR2b pathway dysregulation-related cancer, and the use of the antibody or antibody-drug conjugate in the treatment of an FGFR2b pathway dysregulation-related cancer. Provided are an anti-FGFR2b antibody and the use thereof. Provided are a novel anti-FGFR2b antibody and a nucleic acid encoding the antibody, a vector and a host cell for the expression and production thereof, an antibody-drug conjugate, and a pharmaceutical composition comprising the antibody. Furthermore, the present invention relates to the use of the antibody in the ‌diagnosis‌ of an FGFR2b pathway dysregulation-related cancer, and the use of the antibody or antibody-drug conjugate in the treatment of an FGFR2b pathway dysregulation-related cancer.

[Xiaodan YANG, Shiyou CHEN, Xiuqin ZHU, Linsheng LI, Junji DONG, Guanghui ZHAO, Lijia LI, Xiaofeng CHEN, Wenjia LI] CN Dongguan, Guangdong Provided is a set of viral vectors, comprising: a first viral vector that carries a first nucleic acid molecule encoding an envelope protein, and a second viral vector that carries a second nucleic acid molecule encoding a fusion protein, the fusion protein comprising: a single-chain antibody capable of binding to CD28 or CD3, and a C-terminal domain, comprising a transmembrane region and an intracellular region, of the envelope protein. The C terminal of the single-chain antibody is connected to the N terminal of the C-terminal domain of the envelope protein, and the envelope protein and the fusion protein are in a non-fusion form. Also provided are a method for obtaining a lentivirus and an obtained lentivirus, a method for introducing a lentivirus into an unactivated T lymphocyte, a method for expressing a target gene, a method for obtaining a CAR-T cell and an obtained CAR-T cell, a pharmaceutical composition, and a use thereof.